Company: TVRD
Filing Date: 2025-10-07
Form Type: S-1/A
Source: 0001104659-25-097519
Chunk: 94

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-10-07
Form: S-1/A
Chunk 94
---
, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible, for the Company to continue its business for a substantial period of time. As part of its risk management policy, the Company maintains insurance coverage at levels that it believes are appropriate for its business. However, in the event of an accident or incident at these facilities, the Company cannot assure you that the amounts of insurance will be sufficient to satisfy any damages and losses. If the Company’s facilities, or the manufacturing facilities of the Company’s third-party contract manufacturers, are unable to operate because of an accident or incident or for any other reason, even for a short period of time, any or all of the Company’s research and development programs may be harmed. Risks Related to Ownership of the Company’s Common Stock The market price of the Company’s common stock is expected to be volatile. The market price of the Company’s common stock could be subject to significant fluctuations. Market prices for securities of early-stage pharmaceutical, biotechnology and other life sciences companies have historically been particularly volatile. Some of the factors that may cause the market price of the Company’s common stock to fluctuate include:

| ● | the ability of the Company to obtain regulatory approvals for its product candidates, and delays or failures to obtain such approvals; |

| ● | failure of any of the Company’s product candidates, if approved, to achieve commercial success; |

| ● | failure by the Company to maintain its existing third-party license and supply agreements; |

| ● | failure by the Company or its licensors to prosecute, maintain, or enforce its intellectual property rights; |

| ● | changes in laws or regulations applicable to the Company’s product candidates; |

| ● | any inability to obtain adequate supply of the Company’s product candidates or the inability to do so at acceptable prices; |

| ● | adverse regulatory authority decisions; |

| ● | introduction of new products, services or technologies by the Company’s competitors; |

| ● | failure to meet or exceed financial and development projections the Company may provide to the public; |

| ● | failure to meet or exceed the financial and development projections of the investment community; |

| ● | the perception of the pharmaceutical industry by the public, legislatures, regulators and the investment community; |

| ● | announcements of significant acquisitions, strategic collaborations, joint ventures or capital commitments by the Company or its competitors; |

| ● | disputes or other developments relating to proprietary rights, including patents, litigation matters, and the Company’s ability to obtain patent protection for its technologies